Safety and Tolerability of the Direct Renin Inhibitor Aliskiren: A Pooled Analysis of Clinical Experience in More Than 12,000 Patients With Hypertension
Why the study?
Does aliskiren have a similar safety and tolerability profile compared to placebo and other antihypertensive agents in patients with hypertension?
Population
More than 12,000 patients with hypertension pooled from 12 randomized controlled trials
Comparison
Aliskiren 150 mg and 300 mg daily vs Placebo or active comparators including ACE…
Design
Meta-analysis
Follow-up
up to 36 weeks
Authors
Discussion
Loading...
Member takes
Implication
Supports preferring aliskiren over ACE inhibitors to reduce cough; confirms comparable long-term tolerability to other RAS blockers in hypertension.
Structured PICO
Does aliskiren have a similar safety and tolerability profile compared to placebo and other antihypertensive agents in patients with hypertension?
P
Population
More than 12,000 patients with hypertension pooled from 12 randomized controlled trials
I
Intervention
Aliskiren 150 mg and 300 mg daily
C
Comparator
Placebo (in short-term studies ≤2 months) or active comparators including ACE inhibitors, angiotensin receptor blockers, and thiazide diuretics (in long-term studies >2 months)
O
Outcome
Incidence and types of adverse events (AEs) and laboratory abnormalitiessafety
Aliskiren at doses of 150 mg and 300 mg daily demonstrates a safety and tolerability profile similar to placebo and other RAS blockers, with a lower incidence of cough compared to ACE inhibitors.
Cite This Study
White et al. (2010) studied this question.